Close
Nordic 9Nordic 9

Nan Fung Life Sciences (investor - Venture Capital)

Hong Kong nanfung.com
See something wrong or missing? Let us know
Offices:Hong Kong
Average round investment:36.36M USD
Average number per year:1.0
Distribution: 2021 (1)2019 (1)
Portfolio companies: Iceland Oculis Pharma
Mostly invests in: Iceland Iceland (2) Pharma (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Nan Fung Life Sciences

Name Criteria
Iceland Silfurberg
60%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Common investees countries: Iceland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Tekla Capital Management
57%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Common investees countries: Iceland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States AbbVie Ventures
56%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Green Sands Equity
56%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Hong Kong CR-CP Life Science Fund
56%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden AP4 - Fjärde AP-fonden
56%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States New Leaf Venture Partners
56%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland Roche Venture Fund
56%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Bengt Julander
56%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Honeywell Ventures
56%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top